WO2005002562A1 - The combination of a serotonin reuptake inhibitors and agomelatine - Google Patents

The combination of a serotonin reuptake inhibitors and agomelatine Download PDF

Info

Publication number
WO2005002562A1
WO2005002562A1 PCT/DK2004/000464 DK2004000464W WO2005002562A1 WO 2005002562 A1 WO2005002562 A1 WO 2005002562A1 DK 2004000464 W DK2004000464 W DK 2004000464W WO 2005002562 A1 WO2005002562 A1 WO 2005002562A1
Authority
WO
WIPO (PCT)
Prior art keywords
serotonin reuptake
reuptake inhibitor
serotonin
pharmaceutical composition
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000464
Other languages
English (en)
French (fr)
Inventor
Sandra Willigers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33566216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005002562(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2004253225A priority Critical patent/AU2004253225A1/en
Priority to DE602004031527T priority patent/DE602004031527D1/de
Priority to CA002530880A priority patent/CA2530880A1/en
Priority to DK04738961.4T priority patent/DK1643985T3/da
Priority to US10/558,494 priority patent/US20060205754A1/en
Priority to BRPI0411665-8A priority patent/BRPI0411665A/pt
Priority to EA200600183A priority patent/EA200600183A1/ru
Priority to MXPA06000018A priority patent/MXPA06000018A/es
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to AT04738961T priority patent/ATE499096T1/de
Priority to EP04738961A priority patent/EP1643985B1/en
Priority to JP2006517965A priority patent/JP2007513052A/ja
Publication of WO2005002562A1 publication Critical patent/WO2005002562A1/en
Priority to IS8154A priority patent/IS8154A/is
Priority to IL172965A priority patent/IL172965A0/en
Anticipated expiration legal-status Critical
Priority to NO20060242A priority patent/NO20060242L/no
Priority to US12/764,348 priority patent/US20100267772A1/en
Priority to US13/552,699 priority patent/US20130217776A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.
  • SRI serotonin reuptake inhibitor
  • SSRIs Selective serotonin reuptake inhibitors
  • Augmentation of antidepressant therapy may be accomplished through the co- administration of mood stabilizers such as lithium carbonate or triiodothyronin or by the use of electroshock.
  • agomelatine having the general formula
  • the present invention thus provides:
  • the present invention relates to the use of agomelatine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
  • the present invention relates to the use of agomelatine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
  • the present invention relates to the use as above, of agomelatine, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
  • the anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
  • augmenting covers improving the therapeutic effect and/or potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellular 5-HT.
  • the invention relates to the use of agomelatine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the preparation of a pharmaceutical composition or kit for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
  • the diseases responsive to a serotonin reuptake inhibitor include depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
  • anxiety disorders is as defined above.
  • the present invention relates to the use of agomelatine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients.
  • a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients.
  • such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e.g. in the same tablet or capsule.
  • Such unit dosage forms may contain the active ingredients as a homogenous mixture or in separate compartments of the unit dosage form.
  • the present invention relates to the use of agomelatine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition or kit as above, which is adapted for sequential administration of the active ingredients.
  • such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e.g. discrete tablets or capsules containing either of the active ingredients. These discrete unit dosage forms may be contained in the same container or package, e.g. a blister pack.
  • kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms.
  • the invention also relates to a pharmaceutical composition or kit comprising agomelatine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation in extracellular 5- HT, and optionally pharmaceutically acceptable carriers or diluents.
  • composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above.
  • the present invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering agomelatine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level extracellular serotonin, to an individual in need thereof.
  • the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level extracellular serotonin, comprising administering agomelatine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
  • the individuals which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
  • eating disorders such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
  • anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
  • Agomelatine and the serotonin reuptake inhibitor may be administered simultaneously as described above.
  • the active ingredients may be administered sequentially, e.g. in two discrete unit dosage forms as described above.
  • the compounds claimed therein are described as having affinity for the melatonin receptor.
  • agomelatine co-administration of agomelatine and a serotonin reuptake inhibitor produces a significant increase in the level of serotonin in terminal areas, as measured in microdialysis experiments, compared to the administration of the serotonin reuptake inhibitor alone.
  • Administration of agomelatine alone causes no increase in serotonin levels as measured in microdialysis experiments.
  • serotonin reuptake inhibitors show delayed onset of action. Even in responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms. Agomelatine may provide fast onset of therapeutic effect of serotonin reuptake inhibitors.
  • the use of a combination of agomelatine and a serotonin reuptake inhibitor may greatly reduce the amount of serotonin reuptake inhibitor necessary to treat depression and other affective disorders and may thus reduce the side effects caused by the serotonin reuptake inhibitor.
  • the combination of a reduced amount of SRI and agomelatine may reduce the risk of SSRI-induced sexual dysfunction and sleep disturbances.
  • agomelatine may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60% reduction in symptoms has not been achieved during the first 6 weeks of treatment with an SRI.
  • the following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with agomelatine: citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, iudiprarnine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, milnacipran, apelinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate,
  • Other therapeutic compounds which may benefit from augmentation with agomelatine include compounds, which causes an elevation in the extracellular level of 5-HT in the synaptic cleft, although they are not serotonin reuptake inhibitors.
  • One such compound is tianeptine.
  • SRIs which are particularly preferred according to the present invention include citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine.
  • SSRI selective serotonin reuptake inhibitor
  • SSRIs selective serotonin reuptake inhibitors
  • citalopram escitalopram
  • fluoxetine fluvoxamine
  • sertraline or paroxetine a serotonin reuptake inhibitor
  • the active ingredients according to the invention i.e. agomelatine and the SRI or a compound causing an increase in extracellular serotonin levels, may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the latter being obtainable by reaction of the base form with an appropriate acid.
  • Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram in the form of the oxalate, fluoxetine, sertraline and paroxetine in the form of the hydrochloride and fluvoxamine in the form of the maleate.
  • the combination of agomelatine with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS).
  • CNS central nervous system
  • combination therapy with agomelatine using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.
  • the amount of agomelatine used in combination therapy may range from about 0.1 to about 150 mg/day, particularly from about 0.1 to about 100 mg/day and more particularly from about 0.5 to about 50 mg/day and even more particularly from about 1 to about 5 mg/day.
  • Serotonin reuptake inhibitors including the SSRIs specifically mentioned hereinabove, differ both in molecular weight and in activity. As a consequence, the amount of serotonin reuptake inhibitor used in combination therapy depends on the nature of said serotonin reuptake inhibitor.
  • the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT is administered at lower doses than required when the compound is used alone. In another embodiment, the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT, is administered in normal doses.
  • compositions of this invention an appropriate amount of the active ingredient(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which can take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously or by parenteral injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient(s) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • Agomelatine may be administered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of agomelatine and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act synergistically on the CNS.
  • a composition containing both a serotonin reuptake inhibitor and agomelatine may be particularly convenient.
  • agomelatine and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions.
  • the compositions may be prepared as described hereinabove.
  • the present invention also comprises products containing agomelatine and a serotonin reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatric drug therapy.
  • Such products may comprise, for example, a kit comprising discrete unit dosage forms containing agomelatine and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or pack, e.g. a blister pack.
  • preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/DK2004/000464 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine Ceased WO2005002562A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP04738961A EP1643985B1 (en) 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine
DE602004031527T DE602004031527D1 (de) 2003-07-04 2004-06-29 Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
CA002530880A CA2530880A1 (en) 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine
DK04738961.4T DK1643985T3 (da) 2003-07-04 2004-06-29 Kombinationen af en serotonin-genoptagelseshæmmer og agomelatin
US10/558,494 US20060205754A1 (en) 2003-07-04 2004-06-29 Combination of a serotonin reuptake inhibitors and agomelatine
BRPI0411665-8A BRPI0411665A (pt) 2003-07-04 2004-06-29 uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
EA200600183A EA200600183A1 (ru) 2003-07-04 2004-06-29 Сочетание ингибитора обратного захвата серотонина и агомелатина
MXPA06000018A MXPA06000018A (es) 2003-07-04 2004-06-29 La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina.
AT04738961T ATE499096T1 (de) 2003-07-04 2004-06-29 Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
AU2004253225A AU2004253225A1 (en) 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine
JP2006517965A JP2007513052A (ja) 2003-07-04 2004-06-29 セロトニン再取り込み阻害剤およびアゴメラチンの併用。
IS8154A IS8154A (is) 2003-07-04 2005-11-28 Blanda af serótínín endurupptöku hindra og agómelatíni
IL172965A IL172965A0 (en) 2003-07-04 2006-01-03 The combination of a serotonin reuptake inhibitors and agomelatine
NO20060242A NO20060242L (no) 2003-07-04 2006-01-17 Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
US12/764,348 US20100267772A1 (en) 2003-07-04 2010-04-21 Combination of a Serotonin Reuptake Inhibitor and Agomelatine
US13/552,699 US20130217776A1 (en) 2003-07-04 2012-07-19 Combination of a Serotonin Reuptake Inhibitor and Agomelatine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301031 2003-07-04
DKPA200301031 2003-07-04
US48547903P 2003-07-07 2003-07-07
US60/485,479 2003-07-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/764,348 Continuation US20100267772A1 (en) 2003-07-04 2010-04-21 Combination of a Serotonin Reuptake Inhibitor and Agomelatine

Publications (1)

Publication Number Publication Date
WO2005002562A1 true WO2005002562A1 (en) 2005-01-13

Family

ID=33566216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000464 Ceased WO2005002562A1 (en) 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine

Country Status (17)

Country Link
US (3) US20060205754A1 (enExample)
EP (1) EP1643985B1 (enExample)
JP (1) JP2007513052A (enExample)
KR (1) KR20060032598A (enExample)
CN (1) CN1852706A (enExample)
AR (1) AR047553A1 (enExample)
AT (1) ATE499096T1 (enExample)
AU (1) AU2004253225A1 (enExample)
BR (1) BRPI0411665A (enExample)
CA (1) CA2530880A1 (enExample)
DE (1) DE602004031527D1 (enExample)
DK (1) DK1643985T3 (enExample)
IL (1) IL172965A0 (enExample)
IS (1) IS8154A (enExample)
MX (1) MXPA06000018A (enExample)
NO (1) NO20060242L (enExample)
WO (1) WO2005002562A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028904A1 (fr) * 2005-09-09 2007-03-15 Les Laboratoires Servier Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
EP1842535A1 (fr) 2006-04-07 2007-10-10 Les Laboratoires Servier Utilisation de l'agomélatine pour l'obtention de médicaments destinés au traitement du Trouble Anxiété Généralisée
WO2008035177A3 (en) * 2006-09-18 2008-08-07 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
EA013462B1 (ru) * 2005-04-20 2010-04-30 Ле Лаборатуар Сервье Применение агомелатина для приготовления лекарственных средств, предназначенных для лечения маниакально-депрессивных расстройств
EA014381B1 (ru) * 2005-09-09 2010-10-29 Ле Лаборатуар Сервье Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат
FR2956031A1 (fr) * 2010-02-11 2011-08-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
EP2517700A1 (en) * 2011-04-28 2012-10-31 Zentiva, k.s. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
MD4308C1 (ro) * 2011-06-09 2015-05-31 Les Laboratoires Servier Cocristale noi ale agomelatinei, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
WO2013013060A1 (en) * 2011-07-19 2013-01-24 Lycus, Llc Agomelatine derivatives
WO2014024896A1 (ja) * 2012-08-08 2014-02-13 株式会社メドレックス アゴメラチンを含有する貼付剤組成物
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (fr) 1990-02-27 1991-09-18 Adir Et Compagnie Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0687472A2 (en) 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
EP0701819A2 (en) 1994-09-14 1996-03-20 Pfizer Inc. Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
EP0714663A2 (en) 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997028141A1 (fr) 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
WO1999013877A1 (en) 1997-09-18 1999-03-25 Astrazeneca Ab A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US6617891B2 (en) * 2001-09-26 2003-09-09 Intel Corporation Slew rate at buffers by isolating predriver from driver
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (fr) 1990-02-27 1991-09-18 Adir Et Compagnie Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0447285B1 (fr) 1990-02-27 1993-05-12 Adir Et Compagnie Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0687472A2 (en) 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
EP0701819A2 (en) 1994-09-14 1996-03-20 Pfizer Inc. Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
EP0714663A2 (en) 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997028141A1 (fr) 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
WO1999013877A1 (en) 1997-09-18 1999-03-25 Astrazeneca Ab A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARTIGAS ET AL., TRENDS PHARMACOL. SCI., vol. 14, 1993, pages 262 - 263
BLIER ET AL., J. CLIN. PSYCIPHARMACOL., vol. 7, no. 6, 1987, pages 24S - 35S
BLIER, P. ET AL., TRENDS IN PHARMACOL. SCIENCE, vol. 15, 1994, pages 220
BOURIN MICHEL ET AL: "Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.", JOURNAL OF PSYCHIATRY & NEUROSCIENCE : JPN. MAR 2004, vol. 29, no. 2, March 2004 (2004-03-01), pages 126 - 133, XP009036056, ISSN: 1180-4882 *
CHILMAN-BLAIR ET AL., DRUGS OF THE FUTURE, vol. 28, no. 1, 2003, pages 7 - 13
CHILMAN-BLAIR K ET AL: "Agomelatine. Antidepressant treatment of bipolar disorder, melatonin agonist/5-HT2C antagonist.", DRUGS OF THE FUTURE, vol. 28, no. 1, January 2003 (2003-01-01), pages 7 - 13, XP009036058, ISSN: 0377-8282 *
GARTSIDE, S.E., BR. J. PHARMACOL, vol. 115, 1995, pages 1064 - 1070
HJORTH, S., J. NEUROCHEM, vol. 60, 1993, pages 776 - 779
INNIS, R.B. ET AL., EUR. J. PHARMACOL., vol. 143, 1987, pages 1095 - 204
INVEMIZZI ET AL., BRAIN RES, vol. 584, 1992, pages 322 - 324
MONTGOMERY S A ET AL: "TREATMENT OF DEPRESSION WITH ASSOCIATED ANXIETY: COMPARISONS OF TRICYCLIC ANTIDEPRESSANTS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS", ACTA PSYCHIATRICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DE, vol. 101, no. SUPPL 403, 2000, pages 9 - 16, XP008012233, ISSN: 0001-690X *
MONTGOMERY; JUDGE, ACTA PSYCHIATR. SCAND., vol. 101, no. 403, 2000, pages 9 - 16
PAPP ET AL., NEUROPSYCHOPHARMACOL, vol. 28, no. 4, 2003, pages 694 - 703
PAPP MARIUSZ ET AL: "Effect of agomelatine in the chronic mild stress model of depression in the rat.", NEUROPSYCHOPHARMACOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY. APR 2003, vol. 28, no. 4, April 2003 (2003-04-01), pages 694 - 703, XP009036057, ISSN: 0893-133X *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013462B1 (ru) * 2005-04-20 2010-04-30 Ле Лаборатуар Сервье Применение агомелатина для приготовления лекарственных средств, предназначенных для лечения маниакально-депрессивных расстройств
US7622505B2 (en) 2005-09-09 2009-11-24 Les Laboratoires Servier Association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
WO2007028904A1 (fr) * 2005-09-09 2007-03-15 Les Laboratoires Servier Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
EP1769798A1 (fr) * 2005-09-09 2007-04-04 Les Laboratoires Servier Nouvelle association entre l'agomélatine et un inhibiteur de la recapture de la noradrénaline et les compositions pharmaceutiques qui la contiennent
JP2011088919A (ja) * 2005-09-09 2011-05-06 Lab Servier アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
EA014381B1 (ru) * 2005-09-09 2010-10-29 Ле Лаборатуар Сервье Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат
AU2006209368B2 (en) * 2005-09-09 2012-07-19 Les Laboratoires Servier New association between agomelatine and a noradrenaline reuptake inhibitor and pharmaceutical compositions containing it
JP2007077147A (ja) * 2005-09-09 2007-03-29 Lab Servier アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
FR2890564A1 (fr) * 2005-09-09 2007-03-16 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
AP2615A (en) * 2005-09-09 2013-03-14 Servier Lab New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
AU2007201527B2 (en) * 2006-04-07 2012-08-09 Les Laboratoires Servier Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EA012608B1 (ru) * 2006-04-07 2009-10-30 Ле Лаборатуар Сервье Применение агомелатина в получении лекарственных средств, предназначенных для лечения генерализованного тревожного расстройства
US7960438B2 (en) 2006-04-07 2011-06-14 Les Laboratoires Servier Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
WO2007116136A1 (fr) * 2006-04-07 2007-10-18 Les Laboratoires Servier Utilisation de l ' agomelatine pour l ' obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2899472A1 (fr) * 2006-04-07 2007-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
EP1842535A1 (fr) 2006-04-07 2007-10-10 Les Laboratoires Servier Utilisation de l'agomélatine pour l'obtention de médicaments destinés au traitement du Trouble Anxiété Généralisée
WO2008035177A3 (en) * 2006-09-18 2008-08-07 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
JP2010519319A (ja) * 2007-05-01 2010-06-03 コンサート ファーマシューティカルズ インコーポレイテッド ナフチル（エチル）アセトアミド
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
FR2956031A1 (fr) * 2010-02-11 2011-08-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
WO2011098689A3 (fr) * 2010-02-11 2011-12-08 Les Laboratoires Servier Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
AU2011214190B2 (en) * 2010-02-11 2013-04-18 Les Laboratoires Servier Use of agomelatine for the preparation of drugs for treating obsessive compulsive disorder (OCD)
EA023473B1 (ru) * 2010-02-11 2016-06-30 Ле Лаборатуар Сервье Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
EP2517700A1 (en) * 2011-04-28 2012-10-31 Zentiva, k.s. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
WO2012146371A1 (en) * 2011-04-28 2012-11-01 Zentiva, K.S. Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl]acetamide and methods of their preparation
EA024422B1 (ru) * 2011-04-28 2016-09-30 Зентива, К.С. Фармацевтически приемлемые сокристаллы n-[2-(7-метокси-1-нафтил)этил]ацетамида и способы их получения
US8927771B2 (en) 2011-04-28 2015-01-06 Zentiva K.S. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation
EP2532647B1 (fr) * 2011-06-09 2016-09-28 Les Laboratoires Servier Nouveaux co-cristaux d'agomelatin.
MD4308C1 (ro) * 2011-06-09 2015-05-31 Les Laboratoires Servier Cocristale noi ale agomelatinei, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
ES2403549R1 (es) * 2011-07-28 2013-07-16 Esteve Labor Dr Co-cristales de agomelatina con formadores de co-cristales

Also Published As

Publication number Publication date
AU2004253225A1 (en) 2005-01-13
IL172965A0 (en) 2006-06-11
MXPA06000018A (es) 2006-03-21
EP1643985A1 (en) 2006-04-12
EP1643985B1 (en) 2011-02-23
BRPI0411665A (pt) 2006-08-08
ATE499096T1 (de) 2011-03-15
KR20060032598A (ko) 2006-04-17
US20130217776A1 (en) 2013-08-22
DK1643985T3 (da) 2011-06-06
CA2530880A1 (en) 2005-01-13
JP2007513052A (ja) 2007-05-24
DE602004031527D1 (de) 2011-04-07
US20100267772A1 (en) 2010-10-21
NO20060242L (no) 2006-01-17
US20060205754A1 (en) 2006-09-14
AR047553A1 (es) 2006-01-25
IS8154A (is) 2005-11-28
CN1852706A (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
US20020103249A1 (en) Combination of a serotonin reuptake inhibitor and irindalone
US20120258984A1 (en) 5-htp combination therapy
AU2003240434A1 (en) Combination therapy wherein a serotinin reuptake inhibitor is used
CA2537747A1 (en) The combination of a serotonin reuptake inhibitor and loxapine
US20070042014A1 (en) Combination of a serotonin reuptake inhibitor and loxapine
AU2004296531A1 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
WO2005018676A1 (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
CA2643922A1 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
ZA200509588B (en) The combination of a serotonin reuptake inhibitors and agomelatine
US20080167290A1 (en) Combination of a Serotonin Reuptake Inhibitor and Amoxapine
CA2537757A1 (en) The combination of a serotonin reuptake inhibitor and amoxapine
AU2007353453A1 (en) 5-HTP combination therapy
MXPA06005127A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019138.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 543766

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/09588

Country of ref document: ZA

Ref document number: 200509588

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12005502158

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004738961

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020057024442

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006517965

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2530880

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 06000699

Country of ref document: CO

Ref document number: 50/CHENP/2006

Country of ref document: IN

Ref document number: 2004253225

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000018

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004253225

Country of ref document: AU

Date of ref document: 20040629

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004253225

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200600183

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 10558494

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004738961

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057024442

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0411665

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10558494

Country of ref document: US